Immunotherapy Inside the Cell: The New Frontier of Cancer Therapy

Frost & Sullivan Partner Dorman Followwill comments on one of the disrupting forces that are transforming the healthcare markets

11 Jan, 2016, 07:05 ET from Frost & Sullivan

LONDON, Jan. 11, 2016 /PRNewswire/ -- Healthcare, the world's largest industry, is more than three times the size and value of the financial services sector, and is transforming faster than ever before, driving humanity to rethink the way we approach our health.

Immunotherapy inside the cell is one of the disrupting forces that are shaking the healthcare markets. Frost & Sullivan Senior Partner Dorman Followwill strongly believes that this is the new frontier of cancer therapy: "Immunotherapy inside the cell could be the 'Holy Grail' of cancer treatment and this is making us shift the focus from therapy to cure."

Mr Followwill who was recently quoted in an article published by the authoritative and prestigious "The Life Sciences Report" explains why some companies are leading the way in biotech by looking at how penetrate the cell membrane.

"Cancer cells tend not to be red-flagged by the immune system, but autologous (generated within the patient's body) immunotherapy would unmask the cells so that the immune system could then attack," Followwill explains. "The Holy Grail in oncology therapeutics is to find a way to trigger the body's own immune responses against cancer cells wherever they happen to be presenting."

Sorrento Therapeutics is one of the companies Frost & Sullivan has been watching closely as the Transformational Health team have been looking at the monoclonal antibody field for a long time.

Reflecting on a 2013 visit to the company's headquarters in San Diego, he noted Sorrento had a "full pipeline of oncology candidates. It was really impressive to me. And it had achieved that with a mere 18 employees." That kind of "frugal innovation," which is badly needed by big pharma, sets the company up for continued success, he said.

Frost & Sullivan has recently introduced the Transformational Health program. This program addresses ways companies can innovate and transform themselves during this period of change.

Understanding every aspect of healthcare, as well as the disrupting factors altering the industry, such as engineering, connectivity, customer engagement and business model, is essential for success.

For more information on how transformational health is impacting your organization, and for complimentary access to more information on the program's abilities, please visit: bit.ly/1P2iEgK.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Contact:

Chiara Carella
Corporate Communications – Europe
P: +44 (0) 20 7343 8314
M: +44 (0) 753 3017689
E: chiara.carella@frost.com 
http://www.frost.com

 

SOURCE Frost & Sullivan



RELATED LINKS

http://www.frost.com